As reviewed above, the Wee1 inhibitor adavosertib is able to ameliorate patients’ survival benefits and has the potential to be a good candidate for the treatment of advanced or recurrent/metastatic endometrial cancer. This evidence concerns the gene WEE1 and endometrial cancer.